Editing C-peptide (section)

==Therapeutics==
Therapeutic use of C-peptide has been explored in small clinical trials in diabetic kidney disease.<ref>{{cite journal | vauthors = Brunskill NJ | title = C-peptide and diabetic kidney disease | journal = Journal of Internal Medicine | volume = 281 | issue = 1 | pages = 41–51 | date = January 2017 | pmid = 27640884 | doi = 10.1111/joim.12548 | doi-access = free }}</ref><ref>{{cite journal | vauthors = Shaw JA, Shetty P, Burns KD, Fergusson D, Knoll GA | title = C-peptide as a Therapy for Kidney Disease: A Systematic Review and Meta-Analysis | journal = PLOS ONE | volume = 10 | issue = 5 | pages = e0127439 | date = 2015 | pmid = 25993479 | pmc = 4439165 | doi = 10.1371/journal.pone.0127439 | bibcode = 2015PLoSO..1027439S | doi-access = free }}</ref>  Creative Peptides,<ref>{{cite web|title=C-peptide - Creative Peptides -|url=http://adisinsight.springer.com/drugs/800010430|publisher=AdisInsight|access-date=October 22, 2016|archive-date=September 13, 2018|archive-url=https://web.archive.org/web/20180913002416/https://adisinsight.springer.com/drugs/800010430|url-status=live}}</ref> Eli Lilly,<ref>{{cite web|title=C-peptide - Eli Lilly|url=http://adisinsight.springer.com/drugs/800005551|publisher=AdisInsight|access-date=October 22, 2016|archive-date=September 12, 2018|archive-url=https://web.archive.org/web/20180912204506/https://adisinsight.springer.com/drugs/800005551|url-status=live}}</ref> and Cebix<ref>{{cite web|title=C-peptide long-acting - Cebix|url=http://adisinsight.springer.com/drugs/800034107|website=adisinsight.springer.com|publisher=AdisInsight|access-date=October 22, 2016|archive-date=November 16, 2018|archive-url=https://web.archive.org/web/20181116225545/https://adisinsight.springer.com/drugs/800034107|url-status=live}}</ref> all had [[drug development]] programs for a C-peptide product.   Cebix had the only ongoing program until it completed a Phase IIb trial in December 2014 that showed no difference between C-peptide and placebo, and it terminated its program and went out of business.<ref>{{cite news|last1=Bigelow|first1=Bruce V.|title=Cebix Shuts Down Following Mid-Stage Trial of C-Peptide Drug|url=http://www.xconomy.com/san-diego/2015/02/23/cebix-shuts-down-following-mid-stage-trial-of-c-peptide-drug/|work=Xconomy|date=February 23, 2015|access-date=October 22, 2016|archive-date=December 28, 2018|archive-url=https://web.archive.org/web/20181228223211/https://xconomy.com/san-diego/2015/02/23/cebix-shuts-down-following-mid-stage-trial-of-c-peptide-drug/|url-status=live}}</ref><ref>{{cite news|last1=Garde|first1=Damian|title=Cebix hangs it up after raising $50M for diabetes drug|url=http://www.fiercebiotech.com/r-d/cebix-hangs-it-up-after-raising-50m-for-diabetes-drug|work=FierceBiotech|date=February 24, 2015|access-date=October 22, 2016|archive-date=September 13, 2018|archive-url=https://web.archive.org/web/20180913002325/https://www.fiercebiotech.com/r-d/cebix-hangs-it-up-after-raising-50m-for-diabetes-drug|url-status=live}}</ref>